Epcoritamab SC With Rituximab plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma, Including Patients With POD24: Updated Results From EPCORE NHL-2

被引：0
|
作者：
Merryman, Reid W. [1 ]
Belada, David [2 ,3 ]
Sureda, Anna [4 ]
Leppa, Sirpa [5 ,6 ]
Vermaat, Joost S. P. [7 ]
Holte, Harald [8 ,9 ]
Hutchings, Martin [10 ]
Lugtenburg, Pieternella [11 ]
de Vos, Sven [12 ]
Abrisqueta, Pau [13 ]
Nijland, Marcel [14 ,15 ]
Christensen, Jacob Haaber [16 ]
Wahlin, Bjorn E. [17 ]
Linton, Kim M. [18 ,19 ]
Wang Liwei [20 ]
Abbas, Aqeel [20 ]
Rana, Ali [20 ]
Quadri, Syed [21 ]
Falchi, Lorenzo [22 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] Univ Hosp, Dept Internal Med Hematol 4, Hradec Kralove, Czech Republic
[3] Fac Med, Hradec Kralove, Czech Republic
[4] Univ Barcelona, IDIBELL, Inst Catala Oncol, Hosp Duran i Reynals, Barcelona, Spain
[5] Univ Helsinki, Helsinki, Finland
[6] Helsinki Univ Hosp, Ctr Comprehens Canc, Helsinki, Finland
[7] Leiden Univ, Med Ctr, Leiden, Netherlands
[8] Oslo Univ Hosp, Oslo, Norway
[9] KG Jebsen Ctr B Cell Malignancies, Oslo, Norway
[10] Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark
[11] Erasmus MC Canc Inst, Univ Med Ctr, Dept Hematol, Lunenburg Lymphoma Phase Consortium HOVON LLPC 1, Rotterdam, Netherlands
[12] Ronald Reagan Univ Calif Los Angeles Med Ctr, Los Angeles, CA USA
[13] Hosp Univ Vall dHebron, Barcelona, Spain
[14] Univ Med Ctr Groningen, Groningen, Netherlands
[15] Univ Groningen, Groningen, Netherlands
[16] Odense Univ Hosp, Odense, Denmark
[17] Karolinska Inst, Stockholm, Sweden
[18] Christie NHS Fdn Trust, Manchester, Lancs, England
[19] Manchester Canc Res Ctr, Manchester, Lancs, England
[20] Genmab, Plainsboro, NJ USA
[21] AbbVie, N Chicago, IL USA
[22] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, New York, NY USA
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2023年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P-059
引用
收藏
页码：S37 / S38
页数：2
相关论文
共 50 条
  • [41] Improvements in Lymphoma Symptoms and Health-Related Quality of Life in Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated with Subcutaneous Epcoritamab (EPCORE NHL-1)
    Phillips, Tycel
    Lugtenburg, Pieternella
    Kalsekar, Anupama
    Mutebi, Alex
    Wang, Anthony
    Blaedel, Julie
    Kosa, Katherine
    Martin, Susan
    Sacchi, Mariana
    Thieblemont, Catherine
    BLOOD, 2022, 140 : 8022 - 8023
  • [42] Phase II study of dulanermin plus rituximab in patients with relapsed follicular non-Hodgkin's lymphoma (NHL).
    Belada, D.
    Mayer, J.
    Czuczman, M. S.
    Flinn, I. W.
    Durbin-Johnson, B.
    Bray, G. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [43] Influence of rituximab plus bendamustine chemotherapy on the immune system in patients with refractory or relapsed follicular lymphoma and mantle cell lymphoma
    Ito, Kaori
    Okamoto, Masataka
    Ando, Maiko
    Kakumae, Yukiko
    Okamoto, Akinao
    Inaguma, Yoko
    Tokuda, Masutaka
    Yanada, Masamitsu
    Yamada, Shigeki
    Emi, Nobuhiko
    LEUKEMIA & LYMPHOMA, 2015, 56 (04) : 1123 - 1125
  • [44] Metabolic response rates of epcoritamab plus R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data.
    Falchi, Lorenzo
    Clausen, Michael
    Offner, Fritz
    De Vos, Sven
    Brody, Joshua
    Linton, Kim M.
    Snauwaert, Sylvia
    Cordoba, Raul
    Wu, Jun
    Bykhovski, Irina
    Wang, Liwei
    Rana, Ali
    Belada, David
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [45] Frontline therapy with Bendamustine and rituximab (BR) in Follicular Lymphoma: Prognosis Among Patients with Progression of Disease By 24 Months (POD24) Is Poor with Majority Having Transformed Lymphoma
    Freeman, Ciara Louise
    Savage, Kerry J.
    Villa, Diego
    Scott, David W.
    Gerrie, Alina S.
    Ferguson, David J.
    Cafferty, Fergus
    Slack, Graham W.
    Farinha, Pedro
    Skinnider, Brian
    Connors, Joseph M.
    Sehn, Laurie H.
    BLOOD, 2018, 132
  • [46] Therapy for patients with POD24 follicular lymphoma: Treatment patterns and outcomes from the Lymphoma Epidemiology of Outcomes (LEO) Consortium.
    Casulo, Carla
    Larson, Melissa C.
    Day, Jonathan R.
    Habermann, Thomas Matthew
    Lossos, Izidore S.
    Wang, Yucai
    Nastoupil, Loretta J.
    Strouse, Christopher
    Chihara, Dai
    Martin, Peter
    Cohen, Jonathon Brett
    Kahl, Brad S.
    Ruan, Jia
    Burack, Walter Richard
    Koff, Jean Louise
    Friedberg, Jonathan W.
    Cerhan, James Robert
    Flowers, Christopher
    Link, Brian K.
    Maurer, Matthew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [47] Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial
    Thieblemont, Catherine
    Karimi, Yasmin H.
    Ghesquieres, Herve
    Cheah, Chan Y.
    Clausen, Michael Roost
    Cunningham, David
    Jurczak, Wojciech
    Do, Young Rok
    Gasiorowski, Robin
    Lewis, David John
    Kim, Tae Min
    van der Poel, Marjolein
    Poon, Michelle Limei
    Feldman, Tatyana
    Linton, Kim M.
    Sureda, Anna
    Hutchings, Martin
    Dinh, Minh H.
    Kilavuz, Nurgul
    Soong, David
    Mark, Thomas
    Sacchi, Mariana
    Phillips, Tycel
    Lugtenburg, Pieternella J.
    LEUKEMIA, 2024, : 2653 - 2662
  • [48] Updated interim analysis of the randomized phase 1b/3 study of tazemetostat in combination with lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma.
    Batlevi, Connie Lee
    Park, Steven I.
    Phillips, Tycel Jovelle
    Amengual, Jennifer
    Andorsky, David Jacob
    Campbell, Philip
    Mckay, Pamela
    Leonard, John Paul
    Sondhi, Manu
    Yang, Jay
    Chen, Yingxue
    O'Connor, Heather
    Slatcher, Pamela
    Morschhauser, Franck
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [49] Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Updated Phase 1b Results of Symphony-1 with 22.5 Months Follow-up
    Salles, Gilles
    Park, Steven I.
    Phillips, Tycel J.
    Amengual, Jennifer E.
    Andorsky, David J.
    Campbell, Philip
    McKay, Pamela
    Leonard, John P.
    Chen, Yingxue
    Chen, Jade
    Bannerji, Rajat
    Kapopara, Apoorva
    Szanto, Attila
    Morschhauser, Franck
    BLOOD, 2023, 142
  • [50] Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: Updated results from the pivotal EPCORE NHL-1 trial.
    Karimi, Yasmin
    Ghesquieres, Herve
    Jurczak, Wojciech
    Cheah, Chan
    Clausen, Michael
    Lugtenburg, Pieternella
    Cunningham, David
    Do, Young Rok
    Lewis, David John
    Gasiorowski, Robin
    Kim, Tae Min
    Van der Poel, Marjolein
    Poon, Michelle Li Mei
    Feldman, Tatyana A.
    Linton, Kim M.
    Sureda, Anna
    Hutchings, Martin
    Stirner, Mariana Cota
    Sacchi, Mariana
    Thieblemont, Catherine
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345